Recent studies have converged on the intersection of GLP-1|GIP|GCGR stimulant therapies and dopamine communication. While GIP activators are commonly employed for addressing type 2 diabetes, their unexpected effects on reinforcement circuits, specifically governed by dopaminergic systems, are attracting significant attention. This paper presents… Read More